 WARREN, N.J., March 11, 2021 GLOBE NEWSWIRE -- Bellerophon Therapeutics, Inc. Nasdaq: BLPH Bellerophon or the Company, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and year ended December 31, 2020. 